Raymond L Benza

Summary

Affiliation: Allegheny General Hospital
Country: USA

Publications

  1. doi request reprint One-year experience with intravenous treprostinil for pulmonary arterial hypertension
    Raymond L Benza
    Division of Cardiovascular Diseases, Allegheny General Hospital, Pittsburgh, Pennsylvania 15212, USA
    J Heart Lung Transplant 32:889-96. 2013
  2. doi request reprint Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension
    Raymond L Benza
    Allegheny General Hospital, Pittsburgh, Pennsylvania, USA
    J Heart Lung Transplant 30:1327-33. 2011
  3. doi request reprint Development of prognostic tools in pulmonary arterial hypertension: lessons from modern day registries
    Raymond L Benza
    The Gerald McGinnis Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA 15212, USA
    Thromb Haemost 108:1049-60. 2012
  4. ncbi request reprint An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry
    Raymond L Benza
    Allegheny General Hospital, Pittsburgh, PA 15212, USA
    Chest 142:448-56. 2012
  5. doi request reprint The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension
    Raymond L Benza
    The Gerald McGinnis Cardiovascular Institute, Allegheny General Hospital, 320 E North Ave, 16th Floor, South Tower, Pittsburgh, PA 15212, USA
    Chest 141:354-62. 2012
  6. doi request reprint Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival
    Raymond L Benza
    University of Alabama at Birmingham, 1900 University Blvd, Tinsley Harrison Towers, Room 328A, Birmingham, AL 35294, USA
    Chest 134:775-82. 2008
  7. doi request reprint Role of cardiac magnetic resonance imaging in the management of patients with pulmonary arterial hypertension
    Raymond Benza
    Allegheny General Hospital, Pittsburgh, Pennsylvania 15212, USA
    J Am Coll Cardiol 52:1683-92. 2008
  8. pmc Transforming growth factor-beta polymorphisms and cardiac allograft rejection
    Raymond L Benza
    Division of Cardiovascular Medicine, Allegheny General Hospital, Pittsburgh, Pennsylvania, USA
    J Heart Lung Transplant 28:1057-62. 2009
  9. doi request reprint Analysis of the lung allocation score estimation of risk of death in patients with pulmonary arterial hypertension using data from the REVEAL Registry
    Raymond L Benza
    Division of Cardiology, The Gerald McGinnis Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA, USA
    Transplantation 90:298-305. 2010
  10. doi request reprint Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)
    Raymond L Benza
    The Gerald McGinnis Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA 15212, USA
    Circulation 122:164-72. 2010

Detail Information

Publications48

  1. doi request reprint One-year experience with intravenous treprostinil for pulmonary arterial hypertension
    Raymond L Benza
    Division of Cardiovascular Diseases, Allegheny General Hospital, Pittsburgh, Pennsylvania 15212, USA
    J Heart Lung Transplant 32:889-96. 2013
    ..Continuous IV treprostinil has several potential advantages over IV epoprostenol; however, there has been a lack of published long-term efficacy and safety data on IV treprostinil in PAH...
  2. doi request reprint Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension
    Raymond L Benza
    Allegheny General Hospital, Pittsburgh, Pennsylvania, USA
    J Heart Lung Transplant 30:1327-33. 2011
    ..This study investigated the long-term effects of inhaled treprostinil in patients concurrently receiving oral background therapy...
  3. doi request reprint Development of prognostic tools in pulmonary arterial hypertension: lessons from modern day registries
    Raymond L Benza
    The Gerald McGinnis Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA 15212, USA
    Thromb Haemost 108:1049-60. 2012
    ..Future modifications of modern prognostic equations should be an ongoing goal of the PAH community in order to provide increased accuracy with identification of novel risk factors and prediction of disease course...
  4. ncbi request reprint An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry
    Raymond L Benza
    Allegheny General Hospital, Pittsburgh, PA 15212, USA
    Chest 142:448-56. 2012
    ....
  5. doi request reprint The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension
    Raymond L Benza
    The Gerald McGinnis Cardiovascular Institute, Allegheny General Hospital, 320 E North Ave, 16th Floor, South Tower, Pittsburgh, PA 15212, USA
    Chest 141:354-62. 2012
    ....
  6. doi request reprint Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival
    Raymond L Benza
    University of Alabama at Birmingham, 1900 University Blvd, Tinsley Harrison Towers, Room 328A, Birmingham, AL 35294, USA
    Chest 134:775-82. 2008
    ..Long-term efficacy evaluations are needed to guide therapeutic management. The purpose of this study is to present 1-year observational data with two endothelin antagonists, sitaxsentan and bosentan, in a prospective, open-label study...
  7. doi request reprint Role of cardiac magnetic resonance imaging in the management of patients with pulmonary arterial hypertension
    Raymond Benza
    Allegheny General Hospital, Pittsburgh, Pennsylvania 15212, USA
    J Am Coll Cardiol 52:1683-92. 2008
    ....
  8. pmc Transforming growth factor-beta polymorphisms and cardiac allograft rejection
    Raymond L Benza
    Division of Cardiovascular Medicine, Allegheny General Hospital, Pittsburgh, Pennsylvania, USA
    J Heart Lung Transplant 28:1057-62. 2009
    ..Cytokine gene polymorphisms regulate cytokine expression. We analyzed transforming growth factor-beta (TGF-beta) allelic variation in codon 25 in susceptibility to acute rejection episodes in cardiac transplant recipients...
  9. doi request reprint Analysis of the lung allocation score estimation of risk of death in patients with pulmonary arterial hypertension using data from the REVEAL Registry
    Raymond L Benza
    Division of Cardiology, The Gerald McGinnis Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA, USA
    Transplantation 90:298-305. 2010
    ....
  10. doi request reprint Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)
    Raymond L Benza
    The Gerald McGinnis Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA 15212, USA
    Circulation 122:164-72. 2010
    ..Factors that determine survival in pulmonary arterial hypertension (PAH) drive clinical management. A quantitative survival prediction tool has not been established for research or clinical use...
  11. ncbi request reprint Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials
    Raymond L Benza
    Division of Cardiovascular Diseases, Allegheny General Hospital, Pittsburgh, Pennsylvania 15212, USA
    J Heart Lung Transplant 30:982-9. 2011
    ....
  12. doi request reprint The role of fibrinolytic genes and proteins in the development of allograft vascular disease
    Raymond L Benza
    Division of Cardiovascular Medicine, Allegheny General Hospital, Pittsburgh, Pennsylvania 15212, USA
    J Heart Lung Transplant 30:935-44. 2011
    ..We sought to determine the relative role of PAI-1 and other fibrinolytic proteins in the development of IP...
  13. ncbi request reprint Management of pulmonary arterial hypertension with a focus on combination therapies
    Raymond L Benza
    Department of Medicine Division of Cardiovascular Disease, University of Alabama Birmingham, Birmingham, Alabama 35294 0006, USA
    J Heart Lung Transplant 26:437-46. 2007
    ..The goal of this report is to review the philosophy of combination therapy and present the available data in this area of study...
  14. pmc Alterations in the fibrinolytic cascade post-transplant: evidence of a bimodal expression pattern
    Raymond L Benza
    Department of Medicine, Division of Cardiovascular Disease, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama 35294 0006, USA
    J Heart Lung Transplant 26:494-7. 2007
    ....
  15. doi request reprint Safety and efficacy of ibutilide in heart transplant recipients
    Jose A Tallaj
    Division of Cardiovascular Disease, Section of Heart Failure, Transplantation and Pulmonary Vascular Disease, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    J Heart Lung Transplant 28:505-7. 2009
    ..Ibutilide treatment was successful in all patients, with the arrhythmia recurring early in 1 patient. There were no complications...
  16. ncbi request reprint Post-heart transplant diastolic dysfunction is a risk factor for mortality
    Jose A Tallaj
    Department of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama Department of Medicine, Birmingham VA Medical Center, Birmingham, Alabama, USA
    J Am Coll Cardiol 50:1064-9. 2007
    ..The purpose of this study was to evaluate the incidence and prognostic implication of diastolic dysfunction (DD) occurring in the first year after transplant...
  17. doi request reprint Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan
    Raymond L Benza
    Department of Medicine, Division of Cardiovascular Diseases, University of Alabama at Birmingham, 321 THT, 1900 University Blvd, Birmingham, AL 35294, USA
    Chest 134:139-45. 2008
    ....
  18. ncbi request reprint The impact of arrhythmias in acute heart failure
    Raymond L Benza
    University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
    J Card Fail 10:279-84. 2004
    ..Arrhythmias are common in chronic heart failure and affect outcomes. The incidence and significance of new arrhythmias in acute heart failure, however, are largely unknown...
  19. pmc Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertension
    Robert C Bourge
    University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Cardiovasc Ther 31:38-44. 2013
    ....
  20. ncbi request reprint Efficacy of bosentan in a small cohort of adult patients with pulmonary arterial hypertension related to congenital heart disease
    Raymond L Benza
    Tinsley Harrison Towers, Room 328A, 1900 University Blvd, Birmingham, AL 35294 0006, USA
    Chest 129:1009-15. 2006
    ..This study was designed to assess the tolerability and efficacy of the oral endothelin receptor antagonist bosentan in adult patients with pulmonary arterial hypertension (PAH) related to congenital heart disease (CHD)...
  21. ncbi request reprint Current outcomes following heart transplantation
    James K Kirklin
    University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Semin Thorac Cardiovasc Surg 16:395-403. 2004
    ..Patient-specific risk profiling will play an increasing role in the allocation of transplantation and other emerging therapies for patients with advanced heart failure...
  22. ncbi request reprint Infection in ventricular assist devices: prevention and treatment
    William L Holman
    Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama 35294 0007, USA
    Ann Thorac Surg 75:S48-57. 2003
    ..This paper describes the pathogenesis of MCSS infection, with particular attention to the role of biofilm-forming bacteria. Suggestions are presented for the prevention and treatment of infections in implanted MCSS...
  23. ncbi request reprint Tissue Doppler assessment of longitudinal right and left ventricular strain and strain rate in pulmonary artery hypertension
    Sanjay Rajdev
    Division of Cardiovascular Diseases, University of Alabama at Birmingham, Birmingham, Alabama, 35249, USA
    Echocardiography 23:872-9. 2006
    ..This reduction in left ventricular function was noted in patients with both normal and reduced right ventricular systolic functions by two-dimensional echocardiography...
  24. ncbi request reprint Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan
    Raymond L Benza
    Division of Cardiology, University of Alabama at Birmingham, Birmingham, Alabama 35294 0006, USA
    J Heart Lung Transplant 26:63-9. 2007
    ..Sitaxsentan, an oral, ET(A)-selective endothelin antagonist currently under investigation, may be an alternative treatment option. In this study we evaluate the safety and efficacy of sitaxsentan in patients discontinuing bosentan...
  25. ncbi request reprint Palliation of allograft vasculopathy with transluminal angioplasty: a decade of experience
    Raymond L Benza
    Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama 35294 0006, USA
    J Am Coll Cardiol 43:1973-81. 2004
    ..The goal of this study was to examine the outcomes of percutaneous coronary interventions (PCI) and the predictors for restenosis after cardiac transplantation...
  26. ncbi request reprint Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure
    Jose A Tallaj
    Department of Medicine, Birmingham VA Medical Center, Birmingham, Alabama 35294, USA
    J Heart Lung Transplant 24:2196-201. 2005
    ..Historically, D-induced cardiomyopathy (CMP) has been refractory to therapy. We report our experience with this form of CMP at the University of Alabama at Birmingham...
  27. ncbi request reprint Donor PAI-1 expression inhibits the intimal response of early allograft vascular disease
    Raymond L Benza
    Division of Cardiovascular Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
    J Heart Lung Transplant 22:515-8. 2003
    ..We determined the extent to which plasminogen activator inhibitor type 1 (PAI-1) expression in donor tissue influences intimal proliferation (IP) in a mouse model of AVD...
  28. ncbi request reprint Treatment of end-stage heart disease with outpatient ventricular assist devices
    William L Holman
    Department of Surgery, University of Alabama at Birmingham, 35294 0007, USA
    Ann Thorac Surg 73:1489-93; discussion 1493-4. 2002
    ..This article reviews our experience with VAD therapy from the start of our outpatient program until the present...
  29. ncbi request reprint Strategies for minimizing hyperlipidemia after cardiac transplantation
    James K Kirklin
    Department of Surgery, Division of Cardiothoracic Surgery, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
    Am J Cardiovasc Drugs 2:377-87. 2002
    ..Consensus exists within the transplant community that a HMG-CoA reductase inhibitor such as pravastatin, should be part of the routine post-transplant drug regimen, and persistent hyperlipidemia should be aggressively treated...
  30. pmc Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension
    Amresh Raina
    Allegheny General Hospital, West Penn Allegheny Health System, Pittsburgh, Pennsylvania, USA
    Pulm Circ 3:116-20. 2013
    ....
  31. ncbi request reprint Relative perioperative bradycardia does not lead to adverse outcomes after cardiac transplantation
    Daniel R Goldstein
    Department of Internal Medicine, Division of Cardiovascular Medicine, Yale University School of Medicine, 3FM Cardiology, 333 Cedar St, New Haven CT 06520, USA
    Am J Transplant 3:484-91. 2003
    ..Amiodarone may modify the recipients' immune response by delaying the occurrence of rejection...
  32. pmc α-Galactosidase A expressed in the salivary glands partially corrects organ biochemical deficits in the fabry mouse through endocrine trafficking
    Michael J Passineau
    Division of Cardiovascular Medicine and Allegheny Singer Research Institute, West Penn Allegheny Health System, Pittsburgh, PA 15212, USA
    Hum Gene Ther 22:293-301. 2011
    ..g., adeno-associated virus) for long-term treatment appear to be warranted...
  33. doi request reprint Role of phosphodiesterase-5 inhibitors in heart failure: emerging data and concepts
    Manreet Kanwar
    Department of Medicine, Division of Cardiovascular Diseases, The Cardiovascular Institute at Allegheny General Hospital, 320 East North Ave, Pittsburgh, PA 15212, USA
    Curr Heart Fail Rep 10:26-35. 2013
    ..If the results of these trials are positive, a new avenue for the treatment of HF will open, which will help curtail the societal effects of this costly and morbid disease...
  34. ncbi request reprint Commentary: non-immunologic vascular failure of the transplanted heart
    Raymond L Benza
    University of Alabama at Birmingham, Department of Medicine, 1900 University Boulevard, 321 THT, Birmingham, Alabama 35294 0006, USA
    J Heart Lung Transplant 22:241-3. 2003
  35. ncbi request reprint Macitentan (Opsumit) for the treatment of pulmonary arterial hypertension
    Megan Clarke
    Section of Heart Failure Transplant and Pulmonary Hypertension, Allegheny General Hospital, 320 East North Avenue, Pittsburgh, PA 15212 4772, USA
    Expert Rev Clin Pharmacol 7:415-21. 2014
    ..Previous trials have focused on short-term outcomes, such as improved 6-min walk distance and WHO functional class. ..
  36. doi request reprint World Health Organization Pulmonary Hypertension group 2: pulmonary hypertension due to left heart disease in the adult--a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation
    James C Fang
    Division of Cardiovascular Medicine, Harrington Heart and Vascular Institute, University Hospitals Case Medical Center, Cleveland, OH, USA
    J Heart Lung Transplant 31:913-33. 2012
    ..The review process was facilitated through the peer review process of the Journal of Heart and Lung Transplantation and ultimately endorsed by the leadership of the ISHLT PH Council...
  37. ncbi request reprint Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial
    Mihai Gheorghiade
    Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Ill 60611, USA
    JAMA 291:1963-71. 2004
    ..In contrast to diuretics, the vasopressin antagonist tolvaptan may increase net volume loss in heart failure without adversely affecting electrolytes and renal function...
  38. doi request reprint Pulmonary hypertension associated with sickle cell disease: pathophysiology and rationale for treatment
    Raymond L Benza
    University of Alabama at Birmingham, THT 328A, 1530 3rd Avenue S, Birmingham, AL 35294 0006, USA
    Lung 186:247-54. 2008
    ..Other possible treatments include sildenafil, epoprostenol, and oral arginine. Data from controlled clinical trials are needed to establish the most effective treatment of patients with PH associated with SCD...
  39. doi request reprint The pathophysiology of endothelin in complications after solid organ transplantation: a potential novel therapeutic role for endothelin receptor antagonists
    Amresh Raina
    Section of Heart Failure, Transplant and Pulmonary Hypertension, Allegheny General Hospital, Pittsburgh, PA 15212, USA
    Transplantation 94:885-93. 2012
    ....
  40. ncbi request reprint Cardiac transplant patients response to the (31)P MRS stress test
    William T Evanochko
    Center for NMR Research and Development and the Department of Medicine, Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
    J Heart Lung Transplant 21:522-9. 2002
    ..If transient ischemia is invoked through the (31)P magnetic resonance spectroscopy (MRS) stress test, monitoring of such an event should be achievable and thus implicating possible ischemic involvement...
  41. ncbi request reprint Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial
    Victor F Tapson
    Division of Pulmonary and Critical Care Medicine, Room 351 Bell Building, Duke University Medical Center, Durham, NC 27710, USA
    Chest 129:683-8. 2006
    ..With continuous IV treprostinil having potential advantages over both of the above therapies, we investigated the safety and efficacy of this regimen in patients with PAH...
  42. ncbi request reprint Right ventricular pressure waveform and wave reflection analysis in patients with pulmonary arterial hypertension
    Mustafa Karamanoglu
    NT and D Research, Medtronic Inc, 7000 Central Ave NE, CW320, Fridley, MN 55432, USA
    Chest 132:37-43. 2007
    ..The aim of this study was to investigate whether the RV pressure waveform utilizing an IHM can be used to estimate the magnitude of pressure wave reflection and cardiac index in patients with IPAH in acute settings...
  43. ncbi request reprint Creation of a model comparing 6-minute walk test to metabolic equivalent in evaluating treatment effects in pulmonary arterial hypertension
    Mardi Gomberg-Maitland
    Section of Cardiology, Department of Medicine, University of Chicago, Chicago, Illinois 60637, USA
    J Heart Lung Transplant 26:732-8. 2007
    ..We compared the Naughton-Balke treadmill test reported in exercise metabolic equivalents (METs) with the 6MWT to evaluate whether MET could be a useful tool to assess exercise capacity...
  44. ncbi request reprint Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension
    Mardi Gomberg-Maitland
    Pulmonary Hypertension Center, University of Chicago Hospitals, 5841 South Maryland Avenue, MC 2016, Chicago, IL 60637, USA
    Am J Respir Crit Care Med 172:1586-9. 2005
    ..With the demonstration of bioequivalence between subcutaneous and intravenous treprostinil, intravenous treprostinil may have an overall better risk-benefit profile than intravenous epoprostenol...
  45. doi request reprint Surrogate and combined end points in pulmonary arterial hypertension
    Corey E Ventetuolo
    Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    Proc Am Thorac Soc 5:617-22. 2008
    ..In addition, investigators have advocated the use of combined clinical end points in future clinical trials. The dependence of clinical trials and clinical management on such end points warrants a review of their use...
  46. pmc Clinical risk factors for portopulmonary hypertension
    Steven M Kawut
    Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University College of Physicians and Surgeons, 622 West 168th Street, PH 8E, Room 101, New York, NY 10032, USA
    Hepatology 48:196-203. 2008
    ..24, 95% confidence interval 0.09-0.65, P = 0.005) of portopulmonary hypertension. The severity of liver disease was not related to the risk of portopulmonary hypertension...
  47. doi request reprint Continuous hemodynamic monitoring in patients with pulmonary arterial hypertension
    Robert P Frantz
    Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Heart Lung Transplant 27:780-8. 2008
    ..The purpose of this study was to determine whether an implantable hemodynamic monitor (IHM) could be used to judge the response of pulmonary arterial hypertension (PAH) patients to changes in therapy...
  48. ncbi request reprint Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study
    G Michael Felker
    Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA
    J Am Coll Cardiol 41:997-1003. 2003
    ..The goal of this study was to assess the interaction between heart failure (HF) etiology and response to milrinone in decompensated HF...